ASCO 2019

May 31, 2019

The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019.

Following are the ASCO 2019 posters and presentations:

Title: CTC vs. biopsy tissue sequencing: A concordance analysis of genomic copy number profile from mCRPC patients (pts)

First Author: Howard I. Scher, M.D., FASCO, Memorial Sloan Kettering Cancer Center

Date and Time: Saturday, June 1, 2019, 8:00 am – 11:00 am CT

Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno)

Abstract: 3050

Poster Board: 42

 

Title: Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

First Author: Howard I. Scher, M.D., FASCO, Memorial Sloan Kettering Cancer Center

Date and Time: Saturday, June 1, 2019, 1:15 pm – 4:15 pm CT

Poster Session: Genitourinary(Prostate) Cancer

Abstract: 5075

Poster Board: 187

 

Title: SLFN11 expression in advanced prostate cancer (APC) predicts response to platinum-based chemotherapy (PLT)

First Author: Vincenza Conteduca, M.D., Ph.D., Dana Farber Cancer Institute

Date and Time: Saturday, June 1, 2019, 1:15 pm –4:15 pm CT

Poster Session: Genitourinary (Prostate) Cancer

Abstract: 5065

Poster Board: 177

 

Title: Pamiparib, an investigational PARP inhibitor in patients with metastatic castration-resistant prostate cancer(mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress

First Author: Simon Chowdhury, M.D., Guy’s, King’s and St. Thomas’ Hospitals,and Sarah Cannon Research Institute

Date and Time: Saturday, June 1, 1:15 pm – 4:15 pm CT

Poster Session: Genitourinary (Prostate) Cancer

Abstract: TPS5086

Poster Board: 198a

 

Title: Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi)

First Author: Andrea B.Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH

Date and Time: Monday, June 3, 2019, 1:15 pm – 4:15 pm CT

Poster Session: Genitourinary (Nonprostate) Cancer

Abstract: 4555

Poster Board: 381